Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

pAdVAntage™ Vector Technical Bulletin

Instructions for Use of Product(s)

Literature # TB207

Cotransfection of mammalian cells with the pAdVAntage™ Vector enhances transient protein expression in a variety of cell types by increasing translation initiation. Transfection of mammalian cells with an expression vector often results in suboptimal expression of the protein of interest. Double-stranded RNA (dsRNA)generated during transfection is thought to activate the dsRNA-activated inhibitor (DAI), one of several enzymes involved in the host cell antiviral defense system. DAI phosphorylates the translation initiation factor eIF-2, halting translation and therefore protein production.
However, inhibition of translation by DAI can be overcome with the adenoviral Virus Associated I RNA (VAI RNA) that is produced by RNA polymerase III following co-transfection with the pAdVAntage™ Vector. The VAI RNA binds to DAI, preventing its activation, thereby allowing translation and protein expression. The pAdVAntage™ Vector contains base pairs 9,831–11,555 of the adenovirus type 2 genome on a 1,724bp SalI-HindIII fragment that encodes the virus-associated RNA genes, VAI and VAII.

Printed in USA. Revised 11/06.